



Date: June 26, 2029

To: Mr. Duane White, Acting Director
Medical Safety and Events Assessment Branch
Division of Materials Safety, Security, State, and Tribal Programs (MSST)
Office of Nuclear Material Safety and Safeguards
U.S. Nuclear Regulatory Commission
Washington, DC 20555-0001

From: Peter Selover, Chief Executive Officer
Exubrion Therapeutics, Inc.
5203 Bristol Industrial Way
Buford, GA 30518

Re: Response to NRC April 27, 2020 Request for Additional Information for the review of a hypothetical license amendment for treatment of dogs with Synovetin OA® containing Sn-117m

Dear Mr. White,

On June 17, 2020, the Nuclear Regulatory Commission (NRC) sent Exubrion a second Request for Additional Information (RAI) for the review of a hypothetical license amendment for treatment of dogs with Synovetin OA® containing Sn-117m. This letter transmits our responses.

Attached to this document is our proposed procedure for use of Synovetin OA®, the technical basis for our proposed release criteria, and our responses to the individual RAI comments. The remainder of our package remains unchanged.

You or your staff can reach me by phone or email (details below) with any questions you may have or to raise any other general matters.

Peter Selover
678-733-0420
pselover@exubrion.com

If you have any technical questions, I invite you to contact Dr. Matthew Arno at Foxfire Scientific.

Dr. Matthew Arno
817-995-6762
arno@foxfirescientific.com

I look forward to hearing from you.

Sincerely,

A handwritten signature in black ink that reads "Peter Selover".

Peter Selover
Chief Executive Officer, Exubrion Therapeutics, Inc.
5203 Bristol Industrial Way
Buford, GA 30518
770-831-5243



cc: Irene Wu
Mike Layton
Kevin Williams
Katie Tapp
Matt Arno

5203 Bristol Industrial Way
Buford, GA 30518
770-831-5243